CURE vs VXUS
Direxion Daily Healthcare Bull 3X ETF vs Vanguard Total International Stock ETF
Which is better, CURE or VXUS?
Multi Alternative against Large Cap Blend.
VXUS has a lower expense ratio. CURE led over 1Y and the full window, VXUS over 3Y and 5Y.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | CURE | VXUS |
|---|---|---|
| Expense Ratio | 0.93% | 0.05%Best |
| AUM | $164M | $163.2B |
| Dividend Yield | 0.98% | 2.34% |
| Holdings | 134 | 8,844 |
| YTD Return | +25.93%Best | +10.00% |
| 1Y Return | +60.78%Best | +17.01% |
| 3Y Return (annualized) | +16.35% | +19.55%Best |
| 5Y Return (annualized) | +6.86% | +8.55%Best |
| Volatility (annualized) | 41.8% | 15.1%Best |
| Max Drawdown | -69.2% | -39.9%Best |
| $10,000 over 5 years | $13,934 | $15,071Best |
| Fund Family | Direxion Shares ETF Trust | Vanguard (US) |
| Category | Alternative | Equity |
| Style | Multi Alternative | Large Cap Blend |
| Inception | Jun 15, 2011 | Jan 26, 2011 |
Not shown on this pair: Top 10 Weight.
Volatility and max drawdown are measured over the window both funds cover: Jun 15, 2011 to Oct 14, 2026 (15.3 years).
CURE vs VXUS growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view is available from the range buttons; it is not the opening view here because over the whole period one of these two funds moves so much further than the other that its line would sit flat on the axis.
CURE vs VXUS Performance
Direxion Daily Healthcare Bull 3X ETF (CURE) is an ETF from Direxion Shares ETF Trust and Vanguard Total International Stock ETF (VXUS) is an ETF from Vanguard (US). Over the past year CURE returned +60.78% while VXUS returned +17.01%. Year to date, CURE is up 25.93% versus a gain of 10.00% for VXUS.
Over three years, CURE compounded at +16.35% per year against +19.55% for VXUS; over five years the annualized figures are +6.86% and +8.55% respectively. Across the full 15-year window we track, CURE has the edge at +24.84% annualized vs +4.67%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
CURE has been the more volatile fund, with annualized monthly volatility of 41.8% compared with 15.1% for VXUS. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -69.2% for CURE and -39.9% for VXUS. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.62. They move together some of the time, and apart the rest.
Fees and Cost Over Time
CURE charges 0.93% per year while VXUS charges 0.05%. On a $10,000 position that is $93 vs $5 annually, a gap of $88 per year that compounds over a long holding period. On income, CURE currently yields 0.98% against 2.34% for VXUS.
Holdings Overlap
At least 8.2% of CURE's money is in holdings VXUS also owns.
Stated as a floor: for VXUS, our book for it covers 91.3% of that fund, so a holding it does not list is one we cannot count as shared. The real figure is this or higher.
CURE and VXUS share little of their money.
7 positions in common, counted across the 49 positions we hold weights for in CURE and 8,425 in VXUS, against full books of 134 and 8,844.
Top Shared Holdings
| Stock | Weight in CURE | Weight in VXUS | Difference |
|---|---|---|---|
| 1548:HKGenscript Biotech Corp | 2.39% | 0.01% | 2.38% |
| PME:AUPro Medicus Ltd | 1.77% | 0.02% | 1.75% |
| 6618:HKJD Health International, Inc. | 1.52% | 0.01% | 1.51% |
| 2413:JPM3 Inc|917 | 1.28% | 0.01% | 1.27% |
| ONT:LNOxford Nanopore Technologies P | 0.54% | 0.00% | 0.54% |
| 241:HKAlibaba Health Information Technology Limited Shs | 0.41% | 0.01% | 0.40% |
| GLPG:BRLakefront Biotherapeutics Sponsored Adr (1 Ads : 1 Ordinary) | 0.31% | 0.00% | 0.31% |
You are not choosing between two funds in isolation.
Whichever of CURE and VXUS you pick has to sit alongside everything else you own. Add the rest and see what the combination actually holds.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, CURE or VXUS?
CURE has an expense ratio of 0.93% while VXUS charges 0.05%. VXUS is the cheaper option, by $88 a year on a $10,000 investment.
Which performed better, CURE or VXUS?
Over the past year CURE returned +60.78% vs +17.01% for VXUS, so CURE leads on 1-year performance. Over the longest common window we track (15 years), CURE annualized +24.84% vs +4.67% for VXUS. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, CURE or VXUS?
CURE has been the more volatile fund at 41.8% annualized versus 15.1% for VXUS. Worst drawdown: CURE -69.2% vs VXUS -39.9%.
Should I hold both CURE and VXUS?
CURE and VXUS have a monthly-return correlation of 0.62, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between CURE and VXUS?
At least 8.2% of CURE's money is in holdings VXUS also owns. Our book for VXUS is partial, so the real figure is this or higher. They hold 7 positions in common, counted across the 49 positions we hold weights for in CURE and 8,425 in VXUS.
Which pays a higher dividend, CURE or VXUS?
CURE yields 0.98% while VXUS yields 2.34%, so VXUS currently pays the higher dividend yield.
Is VXUS better than CURE?
VXUS has a lower expense ratio. CURE led over 1Y and the full window, VXUS over 3Y and 5Y. Which one suits a particular account depends on what it is for. This is information, not a recommendation.